#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=Academic editor : Alejandro Sosnik
1-1	0-8	Academic	person[1]	new[1]	appos	1-4[2_1]
1-2	9-15	editor	person[1]	new[1]	_	_
1-3	16-17	:	_	_	_	_
1-4	18-27	Alejandro	person[2]	giv[2]	_	_
1-5	28-34	Sosnik	person[2]	giv[2]	_	_

#Text=1. Introduction
2-1	35-37	1.	_	_	_	_
2-2	38-50	Introduction	abstract	new	_	_

#Text=Drug-delivery systems are difficult to design as there exist various mechanisms that are involved in the release processes of drug .
3-1	51-64	Drug-delivery	abstract[4]	new[4]	coref	5-28[0_4]
3-2	65-72	systems	abstract[4]	new[4]	_	_
3-3	73-76	are	_	_	_	_
3-4	77-86	difficult	_	_	_	_
3-5	87-89	to	_	_	_	_
3-6	90-96	design	abstract	new	coref|none	25-3[189_0]|3-6[0_189]
3-7	97-99	as	_	_	_	_
3-8	100-105	there	_	_	_	_
3-9	106-111	exist	_	_	_	_
3-10	112-119	various	abstract[5]	new[5]	_	_
3-11	120-130	mechanisms	abstract[5]	new[5]	_	_
3-12	131-135	that	_	_	_	_
3-13	136-139	are	_	_	_	_
3-14	140-148	involved	_	_	_	_
3-15	149-151	in	_	_	_	_
3-16	152-155	the	event[7]	new[7]	_	_
3-17	156-163	release	event|event[7]	new|new[7]	_	_
3-18	164-173	processes	event[7]	new[7]	_	_
3-19	174-176	of	event[7]	new[7]	_	_
3-20	177-181	drug	event[7]|substance	new[7]|new	coref	4-8
3-21	182-183	.	_	_	_	_

#Text=Various factors need to be considered for drug delivery , such as the degree of absorption or the diffusion limitations of the drug in the medium .
4-1	184-191	Various	abstract[9]	new[9]	coref	15-6[105_9]
4-2	192-199	factors	abstract[9]	new[9]	_	_
4-3	200-204	need	_	_	_	_
4-4	205-207	to	_	_	_	_
4-5	208-210	be	_	_	_	_
4-6	211-221	considered	_	_	_	_
4-7	222-225	for	_	_	_	_
4-8	226-230	drug	substance|abstract[11]	giv|new[11]	coref|coref|coref|coref	4-22[16_0]|5-12[23_11]|4-22[16_0]|5-12[23_11]
4-9	231-239	delivery	abstract[11]	new[11]	_	_
4-10	240-241	,	abstract[11]	new[11]	_	_
4-11	242-246	such	abstract[11]	new[11]	_	_
4-12	247-249	as	abstract[11]	new[11]	_	_
4-13	250-253	the	abstract[11]|abstract[12]	new[11]|new[12]	_	_
4-14	254-260	degree	abstract[11]|abstract[12]	new[11]|new[12]	_	_
4-15	261-263	of	abstract[11]|abstract[12]	new[11]|new[12]	_	_
4-16	264-274	absorption	abstract[11]|abstract[12]|abstract	new[11]|new[12]|new	_	_
4-17	275-277	or	abstract[11]|abstract[12]	new[11]|new[12]	_	_
4-18	278-281	the	abstract[11]|abstract[12]|abstract[15]	new[11]|new[12]|new[15]	_	_
4-19	282-291	diffusion	abstract[11]|abstract[12]|abstract|abstract[15]	new[11]|new[12]|new|new[15]	coref	15-2
4-20	292-303	limitations	abstract[11]|abstract[12]|abstract[15]	new[11]|new[12]|new[15]	_	_
4-21	304-306	of	abstract[11]|abstract[12]|abstract[15]	new[11]|new[12]|new[15]	_	_
4-22	307-310	the	abstract[11]|abstract[12]|abstract[15]|substance[16]	new[11]|new[12]|new[15]|giv[16]	coref	5-12[0_16]
4-23	311-315	drug	abstract[11]|abstract[12]|abstract[15]|substance[16]	new[11]|new[12]|new[15]|giv[16]	_	_
4-24	316-318	in	abstract[11]|abstract[12]|abstract[15]|substance[16]	new[11]|new[12]|new[15]|giv[16]	_	_
4-25	319-322	the	abstract[11]|abstract[12]|abstract[15]|substance[16]|place[17]	new[11]|new[12]|new[15]|giv[16]|new[17]	_	_
4-26	323-329	medium	abstract[11]|abstract[12]|abstract[15]|substance[16]|place[17]	new[11]|new[12]|new[15]|giv[16]|new[17]	_	_
4-27	330-331	.	_	_	_	_

#Text=In recent years , the use of porous silica materials in drug delivery has attracted a lot of interest due to its potential for the development of systems that are site-specific and that offer time-dependent controlled delivery .
5-1	332-334	In	_	_	_	_
5-2	335-341	recent	time[18]	new[18]	_	_
5-3	342-347	years	time[18]	new[18]	_	_
5-4	348-349	,	_	_	_	_
5-5	350-353	the	abstract[19]	new[19]	_	_
5-6	354-357	use	abstract[19]	new[19]	_	_
5-7	358-360	of	abstract[19]	new[19]	_	_
5-8	361-367	porous	abstract[19]|substance[21]	new[19]|new[21]	ana	6-4[0_21]
5-9	368-374	silica	abstract[19]|organization|substance[21]	new[19]|new|new[21]	coref	6-8
5-10	375-384	materials	abstract[19]|substance[21]	new[19]|new[21]	_	_
5-11	385-387	in	abstract[19]|substance[21]	new[19]|new[21]	_	_
5-12	388-392	drug	abstract[19]|substance[21]|substance|abstract[23]	new[19]|new[21]|giv|giv[23]	ana|coref|ana|coref	5-22[0_23]|7-45|5-22[0_23]|7-45
5-13	393-401	delivery	abstract[19]|substance[21]|abstract[23]	new[19]|new[21]|giv[23]	_	_
5-14	402-405	has	_	_	_	_
5-15	406-415	attracted	_	_	_	_
5-16	416-417	a	_	_	_	_
5-17	418-421	lot	_	_	_	_
5-18	422-424	of	_	_	_	_
5-19	425-433	interest	_	_	_	_
5-20	434-437	due	_	_	_	_
5-21	438-440	to	_	_	_	_
5-22	441-444	its	abstract|abstract[25]	giv|new[25]	coref|coref	5-35[28_0]|5-35[28_0]
5-23	445-454	potential	abstract[25]	new[25]	_	_
5-24	455-458	for	abstract[25]	new[25]	_	_
5-25	459-462	the	abstract[25]|event[26]	new[25]|new[26]	_	_
5-26	463-474	development	abstract[25]|event[26]	new[25]|new[26]	_	_
5-27	475-477	of	abstract[25]|event[26]	new[25]|new[26]	_	_
5-28	478-485	systems	abstract[25]|event[26]|abstract	new[25]|new[26]|giv	_	_
5-29	486-490	that	_	_	_	_
5-30	491-494	are	_	_	_	_
5-31	495-508	site-specific	_	_	_	_
5-32	509-512	and	_	_	_	_
5-33	513-517	that	_	_	_	_
5-34	518-523	offer	_	_	_	_
5-35	524-538	time-dependent	abstract[28]	giv[28]	_	_
5-36	539-549	controlled	abstract[28]	giv[28]	_	_
5-37	550-558	delivery	abstract[28]	giv[28]	_	_
5-38	559-560	.	_	_	_	_

#Text=Given in particular their non-toxic properties , silica aerogels are a special kind of porous silica materials consisting of highly mesoporous nanostructures .
6-1	561-566	Given	_	_	_	_
6-2	567-569	in	_	_	_	_
6-3	570-580	particular	abstract[30]	new[30]	coref	7-8[39_30]
6-4	581-586	their	substance|abstract[30]	giv|new[30]	coref	6-13[34_0]
6-5	587-596	non-toxic	abstract[30]	new[30]	_	_
6-6	597-607	properties	abstract[30]	new[30]	_	_
6-7	608-609	,	_	_	_	_
6-8	610-616	silica	organization|substance[32]	giv|new[32]	coref|coref|coref|coref	6-16|7-5[38_32]|6-16|7-5[38_32]
6-9	617-625	aerogels	substance[32]	new[32]	_	_
6-10	626-629	are	_	_	_	_
6-11	630-631	a	_	_	_	_
6-12	632-639	special	_	_	_	_
6-13	640-644	kind	substance[34]	giv[34]	_	_
6-14	645-647	of	substance[34]	giv[34]	_	_
6-15	648-654	porous	substance[34]	giv[34]	_	_
6-16	655-661	silica	organization|substance[34]	giv|giv[34]	coref	8-4
6-17	662-671	materials	substance[34]	giv[34]	_	_
6-18	672-682	consisting	_	_	_	_
6-19	683-685	of	_	_	_	_
6-20	686-692	highly	object[36]	new[36]	_	_
6-21	693-703	mesoporous	person|object[36]	new|new[36]	_	_
6-22	704-718	nanostructures	object[36]	new[36]	_	_
6-23	719-720	.	_	_	_	_

#Text=The porous structure make the aerogels have many special properties , such as low density ( 1000 kg/m3 to about 1 kg/m3 ) , high porosity ( ~99 % ) and inner surface area ( 1000 m2/g ) , which is necessary for efficient drug loading .
7-1	721-724	The	abstract[37]	new[37]	_	_
7-2	725-731	porous	abstract[37]	new[37]	_	_
7-3	732-741	structure	abstract[37]	new[37]	_	_
7-4	742-746	make	_	_	_	_
7-5	747-750	the	substance[38]	giv[38]	coref	8-4[51_38]
7-6	751-759	aerogels	substance[38]	giv[38]	_	_
7-7	760-764	have	_	_	_	_
7-8	765-769	many	abstract[39]	giv[39]	_	_
7-9	770-777	special	abstract[39]	giv[39]	_	_
7-10	778-788	properties	abstract[39]	giv[39]	_	_
7-11	789-790	,	abstract[39]	giv[39]	_	_
7-12	791-795	such	abstract[39]	giv[39]	_	_
7-13	796-798	as	abstract[39]	giv[39]	_	_
7-14	799-802	low	abstract[39]|abstract[40]	giv[39]|new[40]	_	_
7-15	803-810	density	abstract[39]|abstract[40]	giv[39]|new[40]	_	_
7-16	811-812	(	abstract[39]	giv[39]	_	_
7-17	813-817	1000	abstract[39]|quantity[41]	giv[39]|new[41]	_	_
7-18	818-823	kg/m3	abstract[39]|quantity[41]	giv[39]|new[41]	_	_
7-19	824-826	to	abstract[39]|quantity[41]	giv[39]|new[41]	_	_
7-20	827-832	about	abstract[39]|quantity[41]|quantity[42]	giv[39]|new[41]|new[42]	_	_
7-21	833-834	1	abstract[39]|quantity[41]|quantity[42]	giv[39]|new[41]|new[42]	_	_
7-22	835-840	kg/m3	abstract[39]|quantity[41]|quantity[42]	giv[39]|new[41]|new[42]	_	_
7-23	841-842	)	abstract[39]	giv[39]	_	_
7-24	843-844	,	abstract[39]	giv[39]	_	_
7-25	845-849	high	abstract[39]|abstract[43]	giv[39]|new[43]	_	_
7-26	850-858	porosity	abstract[39]|abstract[43]	giv[39]|new[43]	_	_
7-27	859-860	(	abstract[39]	giv[39]	_	_
7-28	861-864	~99	abstract[39]|quantity[44]	giv[39]|new[44]	_	_
7-29	865-866	%	abstract[39]|quantity[44]	giv[39]|new[44]	_	_
7-30	867-868	)	abstract[39]	giv[39]	_	_
7-31	869-872	and	abstract[39]	giv[39]	_	_
7-32	873-878	inner	abstract[39]|abstract[46]	giv[39]|new[46]	ana	9-21[0_46]
7-33	879-886	surface	abstract[39]|place|abstract[46]	giv[39]|new|new[46]	coref	8-13
7-34	887-891	area	abstract[39]|abstract[46]	giv[39]|new[46]	_	_
7-35	892-893	(	_	_	_	_
7-36	894-898	1000	quantity[47]	new[47]	_	_
7-37	899-903	m2/g	quantity[47]	new[47]	_	_
7-38	904-905	)	_	_	_	_
7-39	906-907	,	_	_	_	_
7-40	908-913	which	_	_	_	_
7-41	914-916	is	_	_	_	_
7-42	917-926	necessary	_	_	_	_
7-43	927-930	for	_	_	_	_
7-44	931-940	efficient	quantity[49]	new[49]	coref	17-9[0_49]
7-45	941-945	drug	substance|quantity[49]	giv|new[49]	coref	8-19[55_0]
7-46	946-953	loading	quantity[49]	new[49]	_	_
7-47	954-955	.	_	_	_	_

#Text=In addition , silica aerogels can be grafted with various groups by surface modification , which could deliver the drug to targeted regions .
8-1	956-958	In	_	_	_	_
8-2	959-967	addition	_	_	_	_
8-3	968-969	,	_	_	_	_
8-4	970-976	silica	organization|substance[51]	giv|giv[51]	coref|coref|coref|coref	11-5|12-5[0_51]|11-5|12-5[0_51]
8-5	977-985	aerogels	substance[51]	giv[51]	_	_
8-6	986-989	can	_	_	_	_
8-7	990-992	be	_	_	_	_
8-8	993-1000	grafted	_	_	_	_
8-9	1001-1005	with	_	_	_	_
8-10	1006-1013	various	person[52]	new[52]	_	_
8-11	1014-1020	groups	person[52]	new[52]	_	_
8-12	1021-1023	by	person[52]	new[52]	_	_
8-13	1024-1031	surface	person[52]|place|abstract[54]	new[52]|giv|new[54]	_	_
8-14	1032-1044	modification	person[52]|abstract[54]	new[52]|new[54]	_	_
8-15	1045-1046	,	_	_	_	_
8-16	1047-1052	which	_	_	_	_
8-17	1053-1058	could	_	_	_	_
8-18	1059-1066	deliver	_	_	_	_
8-19	1067-1070	the	substance[55]	giv[55]	coref	12-18[86_55]
8-20	1071-1075	drug	substance[55]	giv[55]	_	_
8-21	1076-1078	to	substance[55]	giv[55]	_	_
8-22	1079-1087	targeted	substance[55]|place[56]	giv[55]|new[56]	_	_
8-23	1088-1095	regions	substance[55]|place[56]	giv[55]|new[56]	_	_
8-24	1096-1097	.	_	_	_	_

#Text=Trans-resveratrol ( RSV ) , whose full name is non-flavonoid phytoalexin trans-resveratrol , has many biological functions by virtue of its antibacterial , anti-inflammatory , anticancer , anti-thrombosis , anti-hyperlipidemia and anti-lipid peroxidation characteristics .
9-1	1098-1115	Trans-resveratrol	substance	new	coref	9-11[60_0]
9-2	1116-1117	(	_	_	_	_
9-3	1118-1121	RSV	abstract	new	coref	11-8
9-4	1122-1123	)	_	_	_	_
9-5	1124-1125	,	_	_	_	_
9-6	1126-1131	whose	abstract[59]	new[59]	_	_
9-7	1132-1136	full	abstract[59]	new[59]	_	_
9-8	1137-1141	name	abstract[59]	new[59]	_	_
9-9	1142-1144	is	_	_	_	_
9-10	1145-1158	non-flavonoid	_	_	_	_
9-11	1159-1170	phytoalexin	substance[60]	giv[60]	coref	28-7[0_60]
9-12	1171-1188	trans-resveratrol	substance[60]	giv[60]	_	_
9-13	1189-1190	,	_	_	_	_
9-14	1191-1194	has	_	_	_	_
9-15	1195-1199	many	abstract[61]	new[61]	coref	10-1[69_61]
9-16	1200-1210	biological	abstract[61]	new[61]	_	_
9-17	1211-1220	functions	abstract[61]	new[61]	_	_
9-18	1221-1223	by	_	_	_	_
9-19	1224-1230	virtue	abstract[62]	new[62]	_	_
9-20	1231-1233	of	abstract[62]	new[62]	_	_
9-21	1234-1237	its	abstract[62]|abstract|abstract[68]	new[62]|giv|new[68]	_	_
9-22	1238-1251	antibacterial	abstract[62]|abstract[68]	new[62]|new[68]	_	_
9-23	1252-1253	,	abstract[62]|abstract[68]	new[62]|new[68]	_	_
9-24	1254-1271	anti-inflammatory	abstract[62]|abstract[68]	new[62]|new[68]	_	_
9-25	1272-1273	,	abstract[62]|abstract[68]	new[62]|new[68]	_	_
9-26	1274-1284	anticancer	abstract[62]|abstract|abstract[68]	new[62]|new|new[68]	_	_
9-27	1285-1286	,	abstract[62]|abstract[68]	new[62]|new[68]	_	_
9-28	1287-1302	anti-thrombosis	abstract[62]|abstract|abstract[68]	new[62]|new|new[68]	_	_
9-29	1303-1304	,	abstract[62]|abstract[68]	new[62]|new[68]	_	_
9-30	1305-1324	anti-hyperlipidemia	abstract[62]|abstract|abstract[68]	new[62]|new|new[68]	_	_
9-31	1325-1328	and	abstract[62]|abstract[68]	new[62]|new[68]	_	_
9-32	1329-1339	anti-lipid	abstract[62]|abstract[68]	new[62]|new[68]	_	_
9-33	1340-1352	peroxidation	abstract[62]|event|abstract[68]	new[62]|new|new[68]	_	_
9-34	1353-1368	characteristics	abstract[62]|abstract[68]	new[62]|new[68]	_	_
9-35	1369-1370	.	_	_	_	_

#Text=These functions determined resveratrol has many supplementations in treatment of cancer , diabetes , skin disorders and so on .
10-1	1371-1376	These	abstract[69]	giv[69]	_	_
10-2	1377-1386	functions	abstract[69]	giv[69]	_	_
10-3	1387-1397	determined	_	_	_	_
10-4	1398-1409	resveratrol	substance	new	_	_
10-5	1410-1413	has	_	_	_	_
10-6	1414-1418	many	abstract[71]	new[71]	_	_
10-7	1419-1435	supplementations	abstract[71]	new[71]	_	_
10-8	1436-1438	in	abstract[71]	new[71]	_	_
10-9	1439-1448	treatment	abstract[71]|abstract[72]	new[71]|new[72]	_	_
10-10	1449-1451	of	abstract[71]|abstract[72]	new[71]|new[72]	_	_
10-11	1452-1458	cancer	abstract[71]|abstract[72]|abstract	new[71]|new[72]|new	_	_
10-12	1459-1460	,	abstract[71]|abstract[72]	new[71]|new[72]	_	_
10-13	1461-1469	diabetes	abstract[71]|abstract[72]|abstract	new[71]|new[72]|new	_	_
10-14	1470-1471	,	abstract[71]|abstract[72]	new[71]|new[72]	_	_
10-15	1472-1476	skin	abstract[71]|abstract[72]|object|abstract[76]	new[71]|new[72]|new|new[76]	_	_
10-16	1477-1486	disorders	abstract[71]|abstract[72]|abstract[76]	new[71]|new[72]|new[76]	_	_
10-17	1487-1490	and	_	_	_	_
10-18	1491-1493	so	_	_	_	_
10-19	1494-1496	on	_	_	_	_
10-20	1497-1498	.	_	_	_	_

#Text=In this paper , silica aerogel and RSV was chosen as a carrier and a model drug , respectively .
11-1	1499-1501	In	_	_	_	_
11-2	1502-1506	this	abstract[77]	new[77]	coref	21-2[148_77]
11-3	1507-1512	paper	abstract[77]	new[77]	_	_
11-4	1513-1514	,	_	_	_	_
11-5	1515-1521	silica	organization|substance[79]|substance[80]	giv|new[79]|new[80]	coref|coref|coref|coref|coref|coref|coref|coref|coref	21-6|21-5[150_79]|23-12[167_80]|21-6|21-5[150_79]|23-12[167_80]|21-6|21-5[150_79]|23-12[167_80]
11-6	1522-1529	aerogel	substance[79]|substance[80]	new[79]|new[80]	_	_
11-7	1530-1533	and	substance[80]	new[80]	_	_
11-8	1534-1537	RSV	substance[80]|abstract	new[80]|giv	coref	14-12[99_0]
11-9	1538-1541	was	_	_	_	_
11-10	1542-1548	chosen	_	_	_	_
11-11	1549-1551	as	_	_	_	_
11-12	1552-1553	a	_	_	_	_
11-13	1554-1561	carrier	_	_	_	_
11-14	1562-1565	and	_	_	_	_
11-15	1566-1567	a	_	_	_	_
11-16	1568-1573	model	_	_	_	_
11-17	1574-1578	drug	_	_	_	_
11-18	1579-1580	,	_	_	_	_
11-19	1581-1593	respectively	_	_	_	_
11-20	1594-1595	.	_	_	_	_

#Text=Drug-delivery vehicles based on aerogels can be prepared by different methods , such as the addition of the drug during the conventional sol – gel process or during the post treatment of the synthesized aerogels .
12-1	1596-1609	Drug-delivery	object[82]	new[82]	_	_
12-2	1610-1618	vehicles	object[82]	new[82]	_	_
12-3	1619-1624	based	_	_	_	_
12-4	1625-1627	on	_	_	_	_
12-5	1628-1636	aerogels	substance	giv	coref	12-33[92_0]
12-6	1637-1640	can	_	_	_	_
12-7	1641-1643	be	_	_	_	_
12-8	1644-1652	prepared	_	_	_	_
12-9	1653-1655	by	_	_	_	_
12-10	1656-1665	different	abstract[84]	new[84]	_	_
12-11	1666-1673	methods	abstract[84]	new[84]	_	_
12-12	1674-1675	,	abstract[84]	new[84]	_	_
12-13	1676-1680	such	abstract[84]	new[84]	_	_
12-14	1681-1683	as	abstract[84]	new[84]	_	_
12-15	1684-1687	the	abstract[84]|abstract[85]	new[84]|new[85]	_	_
12-16	1688-1696	addition	abstract[84]|abstract[85]	new[84]|new[85]	_	_
12-17	1697-1699	of	abstract[84]|abstract[85]	new[84]|new[85]	_	_
12-18	1700-1703	the	abstract[84]|abstract[85]|substance[86]	new[84]|new[85]|giv[86]	coref	13-3[94_86]
12-19	1704-1708	drug	abstract[84]|abstract[85]|substance[86]	new[84]|new[85]|giv[86]	_	_
12-20	1709-1715	during	abstract[84]|abstract[85]	new[84]|new[85]	_	_
12-21	1716-1719	the	abstract[84]|abstract[85]|substance[87]	new[84]|new[85]|new[87]	_	_
12-22	1720-1732	conventional	abstract[84]|abstract[85]|substance[87]	new[84]|new[85]|new[87]	_	_
12-23	1733-1736	sol	abstract[84]|abstract[85]|substance[87]	new[84]|new[85]|new[87]	_	_
12-24	1737-1738	–	_	_	_	_
12-25	1739-1742	gel	substance|abstract[89]	new|new[89]	coref|coref	13-6[95_89]|13-6[95_89]
12-26	1743-1750	process	abstract[89]	new[89]	_	_
12-27	1751-1753	or	_	_	_	_
12-28	1754-1760	during	_	_	_	_
12-29	1761-1764	the	event[91]	new[91]	_	_
12-30	1765-1769	post	abstract|event[91]	new|new[91]	_	_
12-31	1770-1779	treatment	event[91]	new[91]	_	_
12-32	1780-1782	of	event[91]	new[91]	_	_
12-33	1783-1786	the	event[91]|substance[92]	new[91]|giv[92]	_	_
12-34	1787-1798	synthesized	event[91]|substance[92]	new[91]|giv[92]	_	_
12-35	1799-1807	aerogels	event[91]|substance[92]	new[91]|giv[92]	_	_
12-36	1808-1809	.	_	_	_	_

#Text=We added the drug during the aging process in this work .
13-1	1810-1812	We	person	acc	ana	19-15
13-2	1813-1818	added	_	_	_	_
13-3	1819-1822	the	substance[94]	giv[94]	coref	14-17[100_94]
13-4	1823-1827	drug	substance[94]	giv[94]	_	_
13-5	1828-1834	during	_	_	_	_
13-6	1835-1838	the	abstract[95]	giv[95]	coref	19-10[133_95]
13-7	1839-1844	aging	abstract[95]	giv[95]	_	_
13-8	1845-1852	process	abstract[95]	giv[95]	_	_
13-9	1853-1855	in	abstract[95]	giv[95]	_	_
13-10	1856-1860	this	abstract[95]|abstract[96]	giv[95]|new[96]	coref	20-3[138_96]
13-11	1861-1865	work	abstract[95]|abstract[96]	giv[95]|new[96]	_	_
13-12	1866-1867	.	_	_	_	_

#Text=The alcogel was brought into contactwith an aging solution which contains the RSV , and then the drug diffused into the alcogel pores from the aging solution .
14-1	1868-1871	The	substance[97]	new[97]	coref	16-22[116_97]
14-2	1872-1879	alcogel	substance[97]	new[97]	_	_
14-3	1880-1883	was	_	_	_	_
14-4	1884-1891	brought	_	_	_	_
14-5	1892-1896	into	_	_	_	_
14-6	1897-1908	contactwith	_	_	_	_
14-7	1909-1911	an	substance[98]	new[98]	coref	14-25[102_98]
14-8	1912-1917	aging	substance[98]	new[98]	_	_
14-9	1918-1926	solution	substance[98]	new[98]	_	_
14-10	1927-1932	which	_	_	_	_
14-11	1933-1941	contains	_	_	_	_
14-12	1942-1945	the	abstract[99]	giv[99]	coref	22-13[157_99]
14-13	1946-1949	RSV	abstract[99]	giv[99]	_	_
14-14	1950-1951	,	_	_	_	_
14-15	1952-1955	and	_	_	_	_
14-16	1956-1960	then	_	_	_	_
14-17	1961-1964	the	substance[100]	giv[100]	coref	16-14[114_100]
14-18	1965-1969	drug	substance[100]	giv[100]	_	_
14-19	1970-1978	diffused	_	_	_	_
14-20	1979-1983	into	_	_	_	_
14-21	1984-1987	the	object[101]	new[101]	coref	15-17[0_101]
14-22	1988-1995	alcogel	object[101]	new[101]	_	_
14-23	1996-2001	pores	object[101]	new[101]	_	_
14-24	2002-2006	from	object[101]	new[101]	_	_
14-25	2007-2010	the	object[101]|substance[102]	new[101]|giv[102]	coref	15-24[110_102]
14-26	2011-2016	aging	object[101]|substance[102]	new[101]|giv[102]	_	_
14-27	2017-2025	solution	object[101]|substance[102]	new[101]|giv[102]	_	_
14-28	2026-2027	.	_	_	_	_

#Text=The diffusion rate depends on many factors , such as the size of the molecules and pores , and the initial concentration of the aging solution .
15-1	2028-2031	The	abstract[104]	new[104]	_	_
15-2	2032-2041	diffusion	abstract|abstract[104]	giv|new[104]	coref	19-3
15-3	2042-2046	rate	abstract[104]	new[104]	_	_
15-4	2047-2054	depends	_	_	_	_
15-5	2055-2057	on	_	_	_	_
15-6	2058-2062	many	abstract[105]	giv[105]	_	_
15-7	2063-2070	factors	abstract[105]	giv[105]	_	_
15-8	2071-2072	,	abstract[105]	giv[105]	_	_
15-9	2073-2077	such	abstract[105]	giv[105]	_	_
15-10	2078-2080	as	abstract[105]	giv[105]	_	_
15-11	2081-2084	the	abstract[105]|abstract[106]	giv[105]|new[106]	ana	16-1[0_106]
15-12	2085-2089	size	abstract[105]|abstract[106]	giv[105]|new[106]	_	_
15-13	2090-2092	of	abstract[105]|abstract[106]	giv[105]|new[106]	_	_
15-14	2093-2096	the	abstract[105]|abstract[106]|object[107]	giv[105]|new[106]|new[107]	_	_
15-15	2097-2106	molecules	abstract[105]|abstract[106]|object[107]	giv[105]|new[106]|new[107]	_	_
15-16	2107-2110	and	abstract[105]|abstract[106]	giv[105]|new[106]	_	_
15-17	2111-2116	pores	abstract[105]|abstract[106]|object	giv[105]|new[106]|giv	_	_
15-18	2117-2118	,	abstract[105]	giv[105]	_	_
15-19	2119-2122	and	abstract[105]	giv[105]	_	_
15-20	2123-2126	the	abstract[105]|quantity[109]	giv[105]|new[109]	_	_
15-21	2127-2134	initial	abstract[105]|quantity[109]	giv[105]|new[109]	_	_
15-22	2135-2148	concentration	abstract[105]|quantity[109]	giv[105]|new[109]	_	_
15-23	2149-2151	of	abstract[105]|quantity[109]	giv[105]|new[109]	_	_
15-24	2152-2155	the	abstract[105]|quantity[109]|substance[110]	giv[105]|new[109]|giv[110]	_	_
15-25	2156-2161	aging	abstract[105]|quantity[109]|substance[110]	giv[105]|new[109]|giv[110]	_	_
15-26	2162-2170	solution	abstract[105]|quantity[109]|substance[110]	giv[105]|new[109]|giv[110]	_	_
15-27	2171-2172	.	_	_	_	_

#Text=It must be emphasized that the role of ethanol was simply to dissolve the drug and allow it to diffuse into the alcogel .
16-1	2173-2175	It	abstract	giv	ana	16-18
16-2	2176-2180	must	_	_	_	_
16-3	2181-2183	be	_	_	_	_
16-4	2184-2194	emphasized	_	_	_	_
16-5	2195-2199	that	_	_	_	_
16-6	2200-2203	the	abstract[112]	new[112]	coref	19-6[131_112]
16-7	2204-2208	role	abstract[112]	new[112]	_	_
16-8	2209-2211	of	abstract[112]	new[112]	_	_
16-9	2212-2219	ethanol	abstract[112]|substance	new[112]|new	coref	22-17
16-10	2220-2223	was	_	_	_	_
16-11	2224-2230	simply	_	_	_	_
16-12	2231-2233	to	_	_	_	_
16-13	2234-2242	dissolve	_	_	_	_
16-14	2243-2246	the	substance[114]	giv[114]	coref	17-8[0_114]
16-15	2247-2251	drug	substance[114]	giv[114]	_	_
16-16	2252-2255	and	_	_	_	_
16-17	2256-2261	allow	_	_	_	_
16-18	2262-2264	it	abstract	giv	coref	35-3[240_0]
16-19	2265-2267	to	_	_	_	_
16-20	2268-2275	diffuse	_	_	_	_
16-21	2276-2280	into	_	_	_	_
16-22	2281-2284	the	substance[116]	giv[116]	coref	20-25[144_116]
16-23	2285-2292	alcogel	substance[116]	giv[116]	_	_
16-24	2293-2294	.	_	_	_	_

#Text=Most research focuses only on the total drug loading content , but ignores the drug distribution and load mode in the carrier .
17-1	2295-2299	Most	abstract[117]	new[117]	_	_
17-2	2300-2308	research	abstract[117]	new[117]	_	_
17-3	2309-2316	focuses	_	_	_	_
17-4	2317-2321	only	_	_	_	_
17-5	2322-2324	on	_	_	_	_
17-6	2325-2328	the	abstract[120]	new[120]	_	_
17-7	2329-2334	total	abstract[120]	new[120]	_	_
17-8	2335-2339	drug	substance|abstract[120]	giv|new[120]	coref	17-15
17-9	2340-2347	loading	quantity|abstract[120]	giv|new[120]	coref	23-21
17-10	2348-2355	content	abstract[120]	new[120]	_	_
17-11	2356-2357	,	_	_	_	_
17-12	2358-2361	but	_	_	_	_
17-13	2362-2369	ignores	_	_	_	_
17-14	2370-2373	the	abstract[122]	new[122]	coref	20-19[142_122]
17-15	2374-2378	drug	substance|abstract[122]	giv|new[122]	coref	20-22[143_0]
17-16	2379-2391	distribution	abstract[122]	new[122]	_	_
17-17	2392-2395	and	_	_	_	_
17-18	2396-2400	load	_	_	_	_
17-19	2401-2405	mode	abstract	new	coref	23-20[170_0]
17-20	2406-2408	in	_	_	_	_
17-21	2409-2412	the	place[124]	new[124]	_	_
17-22	2413-2420	carrier	place[124]	new[124]	_	_
17-23	2421-2422	.	_	_	_	_

#Text=Moreover , drug-loading behaviors are commonly studied using adsorption isotherms and adsorption kinetic equations .
18-1	2423-2431	Moreover	_	_	_	_
18-2	2432-2433	,	_	_	_	_
18-3	2434-2446	drug-loading	abstract[125]	new[125]	_	_
18-4	2447-2456	behaviors	abstract[125]	new[125]	_	_
18-5	2457-2460	are	_	_	_	_
18-6	2461-2469	commonly	_	_	_	_
18-7	2470-2477	studied	_	_	_	_
18-8	2478-2483	using	_	_	_	_
18-9	2484-2494	adsorption	abstract|abstract[127]	new|new[127]	coref|coref	18-12|18-12
18-10	2495-2504	isotherms	abstract[127]	new[127]	_	_
18-11	2505-2508	and	_	_	_	_
18-12	2509-2519	adsorption	substance|abstract[129]	giv|new[129]	_	_
18-13	2520-2527	kinetic	abstract[129]	new[129]	_	_
18-14	2528-2537	equations	abstract[129]	new[129]	_	_
18-15	2538-2539	.	_	_	_	_

#Text=However , diffusion also play an important role in the drug-loading process , and we should consider both the effects of diffusion and adsorption/desorption .
19-1	2540-2547	However	_	_	_	_
19-2	2548-2549	,	_	_	_	_
19-3	2550-2559	diffusion	abstract	giv	coref	19-22
19-4	2560-2564	also	_	_	_	_
19-5	2565-2569	play	_	_	_	_
19-6	2570-2572	an	abstract[131]	giv[131]	_	_
19-7	2573-2582	important	abstract[131]	giv[131]	_	_
19-8	2583-2587	role	abstract[131]	giv[131]	_	_
19-9	2588-2590	in	abstract[131]	giv[131]	_	_
19-10	2591-2594	the	abstract[131]|abstract[133]	giv[131]|giv[133]	coref	22-19[160_133]
19-11	2595-2607	drug-loading	abstract[131]|substance|abstract[133]	giv[131]|new|giv[133]	coref	25-8
19-12	2608-2615	process	abstract[131]|abstract[133]	giv[131]|giv[133]	_	_
19-13	2616-2617	,	_	_	_	_
19-14	2618-2621	and	_	_	_	_
19-15	2622-2624	we	person	giv	ana	20-11
19-16	2625-2631	should	_	_	_	_
19-17	2632-2640	consider	_	_	_	_
19-18	2641-2645	both	abstract[135]	new[135]	_	_
19-19	2646-2649	the	abstract[135]	new[135]	_	_
19-20	2650-2657	effects	abstract[135]	new[135]	_	_
19-21	2658-2660	of	abstract[135]	new[135]	_	_
19-22	2661-2670	diffusion	abstract[135]|abstract	new[135]|giv	coref	20-31
19-23	2671-2674	and	abstract[135]	new[135]	_	_
19-24	2675-2696	adsorption/desorption	abstract[135]|abstract	new[135]|new	coref	20-33
19-25	2697-2698	.	_	_	_	_

#Text=So in this work , based on previous study , we have established a fundamental model to study the distribution of a drug in the alcogel and the interaction of diffusion and adsorption/desorption .
20-1	2699-2701	So	_	_	_	_
20-2	2702-2704	in	_	_	_	_
20-3	2705-2709	this	abstract[138]	giv[138]	_	_
20-4	2710-2714	work	abstract[138]	giv[138]	_	_
20-5	2715-2716	,	_	_	_	_
20-6	2717-2722	based	_	_	_	_
20-7	2723-2725	on	_	_	_	_
20-8	2726-2734	previous	abstract[139]	new[139]	_	_
20-9	2735-2740	study	abstract[139]	new[139]	_	_
20-10	2741-2742	,	_	_	_	_
20-11	2743-2745	we	person	giv	ana	22-3
20-12	2746-2750	have	_	_	_	_
20-13	2751-2762	established	_	_	_	_
20-14	2763-2764	a	abstract[141]	new[141]	_	_
20-15	2765-2776	fundamental	abstract[141]	new[141]	_	_
20-16	2777-2782	model	abstract[141]	new[141]	_	_
20-17	2783-2785	to	_	_	_	_
20-18	2786-2791	study	_	_	_	_
20-19	2792-2795	the	abstract[142]	giv[142]	_	_
20-20	2796-2808	distribution	abstract[142]	giv[142]	_	_
20-21	2809-2811	of	abstract[142]	giv[142]	_	_
20-22	2812-2813	a	abstract[142]|substance[143]	giv[142]|giv[143]	coref	23-24[171_143]
20-23	2814-2818	drug	abstract[142]|substance[143]	giv[142]|giv[143]	_	_
20-24	2819-2821	in	abstract[142]|substance[143]	giv[142]|giv[143]	_	_
20-25	2822-2825	the	abstract[142]|substance[143]|place[144]	giv[142]|giv[143]|giv[144]	_	_
20-26	2826-2833	alcogel	abstract[142]|substance[143]|place[144]	giv[142]|giv[143]|giv[144]	_	_
20-27	2834-2837	and	_	_	_	_
20-28	2838-2841	the	abstract[145]	new[145]	_	_
20-29	2842-2853	interaction	abstract[145]	new[145]	_	_
20-30	2854-2856	of	abstract[145]	new[145]	_	_
20-31	2857-2866	diffusion	abstract[145]|abstract	new[145]|giv	coref	24-18
20-32	2867-2870	and	abstract[145]	new[145]	_	_
20-33	2871-2892	adsorption/desorption	abstract[145]|abstract	new[145]|giv	_	_
20-34	2893-2894	.	_	_	_	_

#Text=In this paper , RSV-loaded silica aerogel ( RLSA ) was prepared by freeze-drying .
21-1	2895-2897	In	_	_	_	_
21-2	2898-2902	this	abstract[148]	giv[148]	_	_
21-3	2903-2908	paper	abstract[148]	giv[148]	_	_
21-4	2909-2910	,	_	_	_	_
21-5	2911-2921	RSV-loaded	substance[150]	giv[150]	coref	23-12[166_150]
21-6	2922-2928	silica	organization|substance[150]	giv|giv[150]	coref	23-12
21-7	2929-2936	aerogel	substance[150]	giv[150]	_	_
21-8	2937-2938	(	_	_	_	_
21-9	2939-2943	RLSA	object	new	coref	23-15
21-10	2944-2945	)	_	_	_	_
21-11	2946-2949	was	_	_	_	_
21-12	2950-2958	prepared	_	_	_	_
21-13	2959-2961	by	_	_	_	_
21-14	2962-2975	freeze-drying	abstract	new	_	_
21-15	2976-2977	.	_	_	_	_

#Text=The reason we used freeze drying instead of supercritical drying is that the RSV will lose ethanol during the slow replacement process in supercritical drying .
22-1	2978-2981	The	abstract[153]	new[153]	_	_
22-2	2982-2988	reason	abstract[153]	new[153]	_	_
22-3	2989-2991	we	person	giv	ana	32-1
22-4	2992-2996	used	_	_	_	_
22-5	2997-3003	freeze	_	_	_	_
22-6	3004-3010	drying	abstract	new	coref	22-9[156_0]
22-7	3011-3018	instead	_	_	_	_
22-8	3019-3021	of	_	_	_	_
22-9	3022-3035	supercritical	abstract[156]	giv[156]	coref	22-24[161_156]
22-10	3036-3042	drying	abstract[156]	giv[156]	_	_
22-11	3043-3045	is	_	_	_	_
22-12	3046-3050	that	_	_	_	_
22-13	3051-3054	the	substance[157]	giv[157]	coref	36-4[0_157]
22-14	3055-3058	RSV	substance[157]	giv[157]	_	_
22-15	3059-3063	will	_	_	_	_
22-16	3064-3068	lose	_	_	_	_
22-17	3069-3076	ethanol	substance	giv	coref	41-15
22-18	3077-3083	during	_	_	_	_
22-19	3084-3087	the	abstract[160]	giv[160]	_	_
22-20	3088-3092	slow	abstract[160]	giv[160]	_	_
22-21	3093-3104	replacement	abstract|abstract[160]	new|giv[160]	coref	42-12[273_0]
22-22	3105-3112	process	abstract[160]	giv[160]	_	_
22-23	3113-3115	in	abstract[160]	giv[160]	_	_
22-24	3116-3129	supercritical	abstract[160]|abstract[161]	giv[160]|giv[161]	coref	34-7[234_161]
22-25	3130-3136	drying	abstract[160]|abstract[161]	giv[160]|giv[161]	_	_
22-26	3137-3138	.	_	_	_	_

#Text=A series of characterizations were carried to compare the differences of silica aerogel and RLSA , and better understand the loading mode of the drug in silica aerogel .
23-1	3139-3140	A	abstract[162]	new[162]	_	_
23-2	3141-3147	series	abstract[162]	new[162]	_	_
23-3	3148-3150	of	abstract[162]	new[162]	_	_
23-4	3151-3168	characterizations	abstract[162]|abstract	new[162]|new	_	_
23-5	3169-3173	were	_	_	_	_
23-6	3174-3181	carried	_	_	_	_
23-7	3182-3184	to	_	_	_	_
23-8	3185-3192	compare	_	_	_	_
23-9	3193-3196	the	abstract[164]	new[164]	_	_
23-10	3197-3208	differences	abstract[164]	new[164]	_	_
23-11	3209-3211	of	abstract[164]	new[164]	_	_
23-12	3212-3218	silica	abstract[164]|organization|substance[166]|substance[167]	new[164]|giv|giv[166]|giv[167]	coref|coref|coref|coref|coref|coref|coref|coref|coref	23-27|23-27[173_166]|30-6[207_167]|23-27|23-27[173_166]|30-6[207_167]|23-27|23-27[173_166]|30-6[207_167]
23-13	3219-3226	aerogel	abstract[164]|substance[166]|substance[167]	new[164]|giv[166]|giv[167]	_	_
23-14	3227-3230	and	abstract[164]|substance[167]	new[164]|giv[167]	_	_
23-15	3231-3235	RLSA	abstract[164]|substance[167]|substance	new[164]|giv[167]|giv	coref	28-13
23-16	3236-3237	,	_	_	_	_
23-17	3238-3241	and	_	_	_	_
23-18	3242-3248	better	_	_	_	_
23-19	3249-3259	understand	_	_	_	_
23-20	3260-3263	the	abstract[170]	giv[170]	_	_
23-21	3264-3271	loading	quantity|abstract[170]	giv|giv[170]	_	_
23-22	3272-3276	mode	abstract[170]	giv[170]	_	_
23-23	3277-3279	of	abstract[170]	giv[170]	_	_
23-24	3280-3283	the	abstract[170]|substance[171]	giv[170]|giv[171]	_	_
23-25	3284-3288	drug	abstract[170]|substance[171]	giv[170]|giv[171]	_	_
23-26	3289-3291	in	abstract[170]|substance[171]	giv[170]|giv[171]	_	_
23-27	3292-3298	silica	abstract[170]|substance[171]|organization|substance[173]	giv[170]|giv[171]|giv|giv[173]	coref|coref|coref|coref	28-4|28-4[197_173]|28-4|28-4[197_173]
23-28	3299-3306	aerogel	abstract[170]|substance[171]|substance[173]	giv[170]|giv[171]|giv[173]	_	_
23-29	3307-3308	.	_	_	_	_

#Text=Furthermore , by establishing different boundary conditions and using Fick ’s second law to fit the apparent diffusion coefficient ( the apparent diffusion coefficients are all marked as “ diffusion coefficient ” in the manuscript hereafter for simplicity ) , three kinds of diffusion processes were studied .
24-1	3309-3320	Furthermore	_	_	_	_
24-2	3321-3322	,	_	_	_	_
24-3	3323-3325	by	_	_	_	_
24-4	3326-3338	establishing	_	_	_	_
24-5	3339-3348	different	abstract[175]	new[175]	_	_
24-6	3349-3357	boundary	place|abstract[175]	new|new[175]	_	_
24-7	3358-3368	conditions	abstract[175]	new[175]	_	_
24-8	3369-3372	and	_	_	_	_
24-9	3373-3378	using	_	_	_	_
24-10	3379-3383	Fick	person[176]|abstract[177]	new[176]|new[177]	_	_
24-11	3384-3386	’s	person[176]|abstract[177]	new[176]|new[177]	_	_
24-12	3387-3393	second	abstract[177]	new[177]	_	_
24-13	3394-3397	law	abstract[177]	new[177]	_	_
24-14	3398-3400	to	_	_	_	_
24-15	3401-3404	fit	_	_	_	_
24-16	3405-3408	the	abstract[179]	new[179]	_	_
24-17	3409-3417	apparent	abstract[179]	new[179]	_	_
24-18	3418-3427	diffusion	abstract|abstract[179]	giv|new[179]	coref	24-23
24-19	3428-3439	coefficient	abstract[179]	new[179]	_	_
24-20	3440-3441	(	_	_	_	_
24-21	3442-3445	the	abstract[181]	new[181]	_	_
24-22	3446-3454	apparent	abstract[181]	new[181]	_	_
24-23	3455-3464	diffusion	abstract|abstract[181]	giv|new[181]	coref	24-30
24-24	3465-3477	coefficients	abstract[181]	new[181]	_	_
24-25	3478-3481	are	_	_	_	_
24-26	3482-3485	all	_	_	_	_
24-27	3486-3492	marked	_	_	_	_
24-28	3493-3495	as	_	_	_	_
24-29	3496-3497	“	_	_	_	_
24-30	3498-3507	diffusion	abstract	giv	coref	24-44
24-31	3508-3519	coefficient	_	_	_	_
24-32	3520-3521	”	_	_	_	_
24-33	3522-3524	in	_	_	_	_
24-34	3525-3528	the	object[183]	new[183]	_	_
24-35	3529-3539	manuscript	object[183]	new[183]	_	_
24-36	3540-3549	hereafter	object[183]	new[183]	_	_
24-37	3550-3553	for	object[183]	new[183]	_	_
24-38	3554-3564	simplicity	object[183]|abstract	new[183]|new	ana	25-1
24-39	3565-3566	)	_	_	_	_
24-40	3567-3568	,	_	_	_	_
24-41	3569-3574	three	abstract[185]	new[185]	_	_
24-42	3575-3580	kinds	abstract[185]	new[185]	_	_
24-43	3581-3583	of	abstract[185]	new[185]	_	_
24-44	3584-3593	diffusion	abstract[185]|abstract|abstract[187]	new[185]|giv|new[187]	_	_
24-45	3594-3603	processes	abstract[185]|abstract[187]	new[185]|new[187]	_	_
24-46	3604-3608	were	_	_	_	_
24-47	3609-3616	studied	_	_	_	_
24-48	3617-3618	.	_	_	_	_

#Text=This facilitates the precise design of the drug-loading and -release system .
25-1	3619-3623	This	abstract	giv	_	_
25-2	3624-3635	facilitates	_	_	_	_
25-3	3636-3639	the	abstract[189]	new[189]	_	_
25-4	3640-3647	precise	abstract[189]	new[189]	_	_
25-5	3648-3654	design	abstract[189]	new[189]	_	_
25-6	3655-3657	of	abstract[189]	new[189]	_	_
25-7	3658-3661	the	abstract[189]|abstract[191]	new[189]|new[191]	_	_
25-8	3662-3674	drug-loading	abstract[189]|substance|abstract[191]	new[189]|giv|new[191]	_	_
25-9	3675-3678	and	abstract[189]|abstract[191]	new[189]|new[191]	_	_
25-10	3679-3687	-release	abstract[189]|abstract[191]	new[189]|new[191]	_	_
25-11	3688-3694	system	abstract[189]|abstract[191]	new[189]|new[191]	_	_
25-12	3695-3696	.	_	_	_	_

#Text=2. Results and Discussion
26-1	3697-3699	2.	object[192]	new[192]	_	_
26-2	3700-3707	Results	object[192]	new[192]	_	_
26-3	3708-3711	and	_	_	_	_
26-4	3712-3722	Discussion	abstract	new	_	_

#Text=2.1 .
27-1	3723-3726	2.1	abstract	new	_	_
27-2	3727-3728	.	_	_	_	_

#Text=The Characterization of Silica Aerogel and Trans-Resveratrol ( RSV)-Loaded Silica Aerogel ( RLSA )
28-1	3729-3732	The	abstract[195]	new[195]	_	_
28-2	3733-3749	Characterization	abstract[195]	new[195]	_	_
28-3	3750-3752	of	abstract[195]	new[195]	_	_
28-4	3753-3759	Silica	abstract[195]|organization|substance[197]	new[195]|giv|giv[197]	coref|coref|coref|coref	28-10|28-9[201_197]|28-10|28-9[201_197]
28-5	3760-3767	Aerogel	abstract[195]|substance[197]	new[195]|giv[197]	_	_
28-6	3768-3771	and	abstract[195]	new[195]	_	_
28-7	3772-3789	Trans-Resveratrol	abstract[195]|substance	new[195]|giv	_	_
28-8	3790-3791	(	abstract[195]	new[195]	_	_
28-9	3792-3803	RSV)-Loaded	abstract[195]|person|substance[201]	new[195]|new|giv[201]	_	_
28-10	3804-3810	Silica	abstract[195]|organization|substance[201]	new[195]|giv|giv[201]	coref	30-6
28-11	3811-3818	Aerogel	abstract[195]|substance[201]	new[195]|giv[201]	_	_
28-12	3819-3820	(	_	_	_	_
28-13	3821-3825	RLSA	abstract	giv	coref	30-9
28-14	3826-3827	)	_	_	_	_

#Text=Figure 1
29-1	3828-3834	Figure	object[203]	new[203]	coref	37-1[250_203]
29-2	3835-3836	1	object[203]	new[203]	_	_

#Text=a shows the appearance of silica aerogel and RLSA after freeze drying .
30-1	3837-3838	a	_	_	_	_
30-2	3839-3844	shows	_	_	_	_
30-3	3845-3848	the	abstract[204]	new[204]	_	_
30-4	3849-3859	appearance	abstract[204]	new[204]	_	_
30-5	3860-3862	of	abstract[204]	new[204]	_	_
30-6	3863-3869	silica	abstract[204]|organization|substance[206]|substance[207]	new[204]|giv|new[206]|giv[207]	coref|coref|coref|coref|coref|coref	32-13|32-13[215_206]|32-13|32-13[215_206]|32-13|32-13[215_206]
30-7	3870-3877	aerogel	abstract[204]|substance[206]|substance[207]	new[204]|new[206]|giv[207]	_	_
30-8	3878-3881	and	abstract[204]|substance[207]	new[204]|giv[207]	_	_
30-9	3882-3886	RLSA	abstract[204]|substance[207]|object	new[204]|giv[207]|giv	coref	32-8[213_0]
30-10	3887-3892	after	_	_	_	_
30-11	3893-3899	freeze	_	_	_	_
30-12	3900-3906	drying	_	_	_	_
30-13	3907-3908	.	_	_	_	_

#Text=The mass of both is 200 mg .
31-1	3909-3912	The	quantity[209]	new[209]	_	_
31-2	3913-3917	mass	quantity[209]	new[209]	_	_
31-3	3918-3920	of	quantity[209]	new[209]	_	_
31-4	3921-3925	both	quantity[209]	new[209]	_	_
31-5	3926-3928	is	_	_	_	_
31-6	3929-3932	200	quantity[210]	new[210]	_	_
31-7	3933-3935	mg	quantity[210]	new[210]	_	_
31-8	3936-3937	.	_	_	_	_

#Text=We can see that the volume of the RLSA is larger than silica aerogel , and the color becomes more opaque .
32-1	3938-3940	We	person	giv	_	_
32-2	3941-3944	can	_	_	_	_
32-3	3945-3948	see	_	_	_	_
32-4	3949-3953	that	_	_	_	_
32-5	3954-3957	the	abstract[212]	new[212]	_	_
32-6	3958-3964	volume	abstract[212]	new[212]	_	_
32-7	3965-3967	of	abstract[212]	new[212]	_	_
32-8	3968-3971	the	abstract[212]|object[213]	new[212]|giv[213]	_	_
32-9	3972-3976	RLSA	abstract[212]|object[213]	new[212]|giv[213]	_	_
32-10	3977-3979	is	_	_	_	_
32-11	3980-3986	larger	_	_	_	_
32-12	3987-3991	than	_	_	_	_
32-13	3992-3998	silica	organization|substance[215]	giv|giv[215]	coref|coref|coref|coref	33-10|33-10[223_215]|33-10|33-10[223_215]
32-14	3999-4006	aerogel	substance[215]	giv[215]	_	_
32-15	4007-4008	,	_	_	_	_
32-16	4009-4012	and	_	_	_	_
32-17	4013-4016	the	abstract[216]	new[216]	_	_
32-18	4017-4022	color	abstract[216]	new[216]	_	_
32-19	4023-4030	becomes	_	_	_	_
32-20	4031-4035	more	_	_	_	_
32-21	4036-4042	opaque	_	_	_	_
32-22	4043-4044	.	_	_	_	_

#Text=A transmission electron microscope ( TEM ) image of silica aerogel shows that it is a dense structure formed by the accumulation of spherical particles , which is consistent with a scanning electron microscope ( SEM ) image .
33-1	4045-4046	A	object[219]	new[219]	coref	33-31[229_219]
33-2	4047-4059	transmission	organization|object[219]	new|new[219]	_	_
33-3	4060-4068	electron	substance|object[219]	new|new[219]	coref	33-33
33-4	4069-4079	microscope	object[219]	new[219]	_	_
33-5	4080-4081	(	_	_	_	_
33-6	4082-4085	TEM	abstract	new	_	_
33-7	4086-4087	)	_	_	_	_
33-8	4088-4093	image	abstract[221]	new[221]	ana	33-14[0_221]
33-9	4094-4096	of	abstract[221]	new[221]	_	_
33-10	4097-4103	silica	abstract[221]|organization|substance[223]	new[221]|giv|giv[223]	coref|coref|coref|coref	34-4|34-3[233_223]|34-4|34-3[233_223]
33-11	4104-4111	aerogel	abstract[221]|substance[223]	new[221]|giv[223]	_	_
33-12	4112-4117	shows	_	_	_	_
33-13	4118-4122	that	_	_	_	_
33-14	4123-4125	it	abstract	giv	coref	33-16[225_0]
33-15	4126-4128	is	_	_	_	_
33-16	4129-4130	a	abstract[225]	giv[225]	coref	33-38[0_225]
33-17	4131-4136	dense	abstract[225]	giv[225]	_	_
33-18	4137-4146	structure	abstract[225]	giv[225]	_	_
33-19	4147-4153	formed	_	_	_	_
33-20	4154-4156	by	_	_	_	_
33-21	4157-4160	the	abstract[226]	new[226]	_	_
33-22	4161-4173	accumulation	abstract[226]	new[226]	_	_
33-23	4174-4176	of	abstract[226]	new[226]	_	_
33-24	4177-4186	spherical	abstract[226]|object[227]	new[226]|new[227]	_	_
33-25	4187-4196	particles	abstract[226]|object[227]	new[226]|new[227]	_	_
33-26	4197-4198	,	_	_	_	_
33-27	4199-4204	which	_	_	_	_
33-28	4205-4207	is	_	_	_	_
33-29	4208-4218	consistent	_	_	_	_
33-30	4219-4223	with	_	_	_	_
33-31	4224-4225	a	object[229]	giv[229]	appos	33-36[0_229]
33-32	4226-4234	scanning	object[229]	giv[229]	_	_
33-33	4235-4243	electron	substance|object[229]	giv|giv[229]	_	_
33-34	4244-4254	microscope	object[229]	giv[229]	_	_
33-35	4255-4256	(	_	_	_	_
33-36	4257-4260	SEM	object	giv	_	_
33-37	4261-4262	)	_	_	_	_
33-38	4263-4268	image	abstract	giv	coref	34-10[237_0]
33-39	4269-4270	.	_	_	_	_

#Text=Compared with the silica aerogel after supercritical drying , its skeleton structure is denser and the density is larger .
34-1	4271-4279	Compared	_	_	_	_
34-2	4280-4284	with	_	_	_	_
34-3	4285-4288	the	substance[233]	giv[233]	ana	34-10[0_233]
34-4	4289-4295	silica	organization|substance[233]	giv|giv[233]	coref	40-19
34-5	4296-4303	aerogel	substance[233]	giv[233]	_	_
34-6	4304-4309	after	_	_	_	_
34-7	4310-4323	supercritical	abstract[234]	giv[234]	coref	43-2[275_234]
34-8	4324-4330	drying	abstract[234]	giv[234]	_	_
34-9	4331-4332	,	_	_	_	_
34-10	4333-4336	its	substance|abstract[237]	giv|giv[237]	_	_
34-11	4337-4345	skeleton	person|abstract[237]	new|giv[237]	coref	40-17[260_0]
34-12	4346-4355	structure	abstract[237]	giv[237]	_	_
34-13	4356-4358	is	_	_	_	_
34-14	4359-4365	denser	_	_	_	_
34-15	4366-4369	and	_	_	_	_
34-16	4370-4373	the	quantity[238]	new[238]	_	_
34-17	4374-4381	density	quantity[238]	new[238]	_	_
34-18	4382-4384	is	_	_	_	_
34-19	4385-4391	larger	_	_	_	_
34-20	4392-4393	.	_	_	_	_

#Text=However , the pore size is smaller and most of it consists of micropores .
35-1	4394-4401	However	_	_	_	_
35-2	4402-4403	,	_	_	_	_
35-3	4404-4407	the	abstract[240]	giv[240]	ana	35-11[0_240]
35-4	4408-4412	pore	abstract|abstract[240]	new|giv[240]	coref	41-22[266_0]
35-5	4413-4417	size	abstract[240]	giv[240]	_	_
35-6	4418-4420	is	_	_	_	_
35-7	4421-4428	smaller	_	_	_	_
35-8	4429-4432	and	_	_	_	_
35-9	4433-4437	most	_	_	_	_
35-10	4438-4440	of	_	_	_	_
35-11	4441-4443	it	abstract	giv	coref	36-11[247_0]
35-12	4444-4452	consists	_	_	_	_
35-13	4453-4455	of	_	_	_	_
35-14	4456-4466	micropores	object	new	_	_
35-15	4467-4468	.	_	_	_	_

#Text=The structure of RSV has a long rod shape with the size on the order of micrometers shown in
36-1	4469-4472	The	abstract[243]	new[243]	_	_
36-2	4473-4482	structure	abstract[243]	new[243]	_	_
36-3	4483-4485	of	abstract[243]	new[243]	_	_
36-4	4486-4489	RSV	abstract[243]|abstract	new[243]|giv	coref	40-5[255_0]
36-5	4490-4493	has	_	_	_	_
36-6	4494-4495	a	abstract[246]	new[246]	coref	40-9[257_246]
36-7	4496-4500	long	abstract[246]	new[246]	_	_
36-8	4501-4504	rod	object|abstract[246]	new|new[246]	coref	40-12
36-9	4505-4510	shape	abstract[246]	new[246]	_	_
36-10	4511-4515	with	abstract[246]	new[246]	_	_
36-11	4516-4519	the	abstract[246]|abstract[247]	new[246]|giv[247]	_	_
36-12	4520-4524	size	abstract[246]|abstract[247]	new[246]|giv[247]	_	_
36-13	4525-4527	on	abstract[246]|abstract[247]	new[246]|giv[247]	_	_
36-14	4528-4531	the	abstract[246]|abstract[247]|abstract[248]	new[246]|giv[247]|new[248]	ana	38-2[0_248]
36-15	4532-4537	order	abstract[246]|abstract[247]|abstract[248]	new[246]|giv[247]|new[248]	_	_
36-16	4538-4540	of	abstract[246]|abstract[247]|abstract[248]	new[246]|giv[247]|new[248]	_	_
36-17	4541-4552	micrometers	abstract[246]|abstract[247]|abstract[248]|abstract	new[246]|giv[247]|new[248]|new	_	_
36-18	4553-4558	shown	_	_	_	_
36-19	4559-4561	in	_	_	_	_

#Text=Figure 1
37-1	4562-4568	Figure	object[250]	giv[250]	coref	39-1[252_250]
37-2	4569-4570	1	object[250]	giv[250]	_	_

#Text=e. It can be seen from
38-1	4571-4573	e.	_	_	_	_
38-2	4574-4576	It	abstract	giv	_	_
38-3	4577-4580	can	_	_	_	_
38-4	4581-4583	be	_	_	_	_
38-5	4584-4588	seen	_	_	_	_
38-6	4589-4593	from	_	_	_	_

#Text=Figure 1
39-1	4594-4600	Figure	object[252]	giv[252]	_	_
39-2	4601-4602	1	object[252]	giv[252]	_	_

#Text=c , f that the recrystallized RSV with a micron-sized long rod shape is integrated with the dense silica network skeleton .
40-1	4603-4604	c	abstract	new	appos	40-3[254_0]
40-2	4605-4606	,	_	_	_	_
40-3	4607-4608	f	abstract[254]	giv[254]	ana	41-1[0_254]
40-4	4609-4613	that	abstract[254]	giv[254]	_	_
40-5	4614-4617	the	abstract[254]|abstract[255]	giv[254]|giv[255]	coref	41-7[262_255]
40-6	4618-4632	recrystallized	abstract[254]|abstract[255]	giv[254]|giv[255]	_	_
40-7	4633-4636	RSV	abstract[254]|abstract[255]	giv[254]|giv[255]	_	_
40-8	4637-4641	with	abstract[254]|abstract[255]	giv[254]|giv[255]	_	_
40-9	4642-4643	a	abstract[254]|abstract[255]|abstract[257]	giv[254]|giv[255]|giv[257]	_	_
40-10	4644-4656	micron-sized	abstract[254]|abstract[255]|abstract[257]	giv[254]|giv[255]|giv[257]	_	_
40-11	4657-4661	long	abstract[254]|abstract[255]|abstract[257]	giv[254]|giv[255]|giv[257]	_	_
40-12	4662-4665	rod	abstract[254]|abstract[255]|object|abstract[257]	giv[254]|giv[255]|giv|giv[257]	_	_
40-13	4666-4671	shape	abstract[254]|abstract[255]|abstract[257]	giv[254]|giv[255]|giv[257]	_	_
40-14	4672-4674	is	abstract[254]	giv[254]	_	_
40-15	4675-4685	integrated	abstract[254]	giv[254]	_	_
40-16	4686-4690	with	_	_	_	_
40-17	4691-4694	the	person[260]	giv[260]	_	_
40-18	4695-4700	dense	person[260]	giv[260]	_	_
40-19	4701-4707	silica	object|person[260]	giv|giv[260]	coref	41-25
40-20	4708-4715	network	place|person[260]	new|giv[260]	_	_
40-21	4716-4724	skeleton	person[260]	giv[260]	_	_
40-22	4725-4726	.	_	_	_	_

#Text=This is may be due to the RSV dissolving into small molecules in an ethanol solution , which can diffuse into the pores of silica alcogel .
41-1	4727-4731	This	abstract	giv	_	_
41-2	4732-4734	is	_	_	_	_
41-3	4735-4738	may	_	_	_	_
41-4	4739-4741	be	_	_	_	_
41-5	4742-4745	due	_	_	_	_
41-6	4746-4748	to	_	_	_	_
41-7	4749-4752	the	abstract[262]	giv[262]	coref	42-3[0_262]
41-8	4753-4756	RSV	abstract[262]	giv[262]	_	_
41-9	4757-4767	dissolving	_	_	_	_
41-10	4768-4772	into	_	_	_	_
41-11	4773-4778	small	substance[263]	new[263]	_	_
41-12	4779-4788	molecules	substance[263]	new[263]	_	_
41-13	4789-4791	in	substance[263]	new[263]	_	_
41-14	4792-4794	an	substance[263]|substance[265]	new[263]|new[265]	_	_
41-15	4795-4802	ethanol	substance[263]|substance|substance[265]	new[263]|giv|new[265]	_	_
41-16	4803-4811	solution	substance[263]|substance[265]	new[263]|new[265]	_	_
41-17	4812-4813	,	_	_	_	_
41-18	4814-4819	which	_	_	_	_
41-19	4820-4823	can	_	_	_	_
41-20	4824-4831	diffuse	_	_	_	_
41-21	4832-4836	into	_	_	_	_
41-22	4837-4840	the	abstract[266]	giv[266]	_	_
41-23	4841-4846	pores	abstract[266]	giv[266]	_	_
41-24	4847-4849	of	abstract[266]	giv[266]	_	_
41-25	4850-4856	silica	abstract[266]|organization|substance[268]	giv[266]|giv|new[268]	_	_
41-26	4857-4864	alcogel	abstract[266]|substance[268]	giv[266]|new[268]	_	_
41-27	4865-4866	.	_	_	_	_

#Text=However , RSV precipitates due to minimal solubility in water during solvent replacement .
42-1	4867-4874	However	_	_	_	_
42-2	4875-4876	,	_	_	_	_
42-3	4877-4880	RSV	substance	giv	coref	43-9[277_0]
42-4	4881-4893	precipitates	_	_	_	_
42-5	4894-4897	due	_	_	_	_
42-6	4898-4900	to	_	_	_	_
42-7	4901-4908	minimal	substance[270]	new[270]	_	_
42-8	4909-4919	solubility	substance[270]	new[270]	_	_
42-9	4920-4922	in	substance[270]	new[270]	_	_
42-10	4923-4928	water	substance[270]|substance	new[270]|new	_	_
42-11	4929-4935	during	_	_	_	_
42-12	4936-4943	solvent	substance|abstract[273]	new|giv[273]	coref|coref	43-5[276_0]|43-5[276_0]
42-13	4944-4955	replacement	abstract[273]	giv[273]	_	_
42-14	4956-4957	.	_	_	_	_

#Text=After freeze drying , the solvent evaporates and the RSV recrystallizes .
43-1	4958-4963	After	_	_	_	_
43-2	4964-4970	freeze	abstract|abstract[275]	new|giv[275]	_	_
43-3	4971-4977	drying	abstract[275]	giv[275]	_	_
43-4	4978-4979	,	_	_	_	_
43-5	4980-4983	the	substance[276]	giv[276]	_	_
43-6	4984-4991	solvent	substance[276]	giv[276]	_	_
43-7	4992-5002	evaporates	_	_	_	_
43-8	5003-5006	and	_	_	_	_
43-9	5007-5010	the	substance[277]	giv[277]	_	_
43-10	5011-5014	RSV	substance[277]	giv[277]	_	_
43-11	5015-5029	recrystallizes	_	_	_	_
43-12	5030-5031	.	_	_	_	_
